Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future
D Akhoundova, MA Rubin - Cancer Cell, 2022 - cell.com
Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …
through the identification of therapeutic targets and molecular biomarkers, leading to the …
The Lancet Commission on prostate cancer: planning for the surge in cases
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
MR Smith, HI Scher, S Sandhu, E Efstathiou… - The Lancet …, 2022 - thelancet.com
Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
JK Lee, S Sivakumar, AB Schrock, R Madison… - NPJ Precision …, 2022 - nature.com
Recent clinical development of KRAS inhibitors has heightened interest in the genomic
landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered …
landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered …
[HTML][HTML] Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Background Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated
into the clinical management of patients with advanced cancer. Beyond tumor profiling …
into the clinical management of patients with advanced cancer. Beyond tumor profiling …
Tumor fraction correlates with detection of actionable variants across> 23,000 circulating tumor DNA samples
H Husain, DC Pavlick, BJ Fendler… - JCO Precision …, 2022 - ascopubs.org
PURPOSE Profiling of circulating tumor DNA (ctDNA) is increasingly adopted in the
management of solid tumors, concurrent with increased availability of more comprehensive …
management of solid tumors, concurrent with increased availability of more comprehensive …
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …
Concurrent tissue and circulating tumor DNA Molecular profiling to detect guideline-based targeted mutations in a multicancer cohort
Importance Tissue-based next-generation sequencing (NGS) of solid tumors is the criterion
standard for identifying somatic mutations that can be treated with National Comprehensive …
standard for identifying somatic mutations that can be treated with National Comprehensive …
Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …